CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Autologous Killer Cell Injection Induced by Dendritic Dells Loaded With 6B11 Anti-idiotype Minibody (6b11 - OCIK Injection) Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03542669
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:47.002357+00:00
Published At: 2022-03-02T00:00:00+00:00
Record Updated At: 2022-03-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Ovarian Carcinoma", "Platinum-resistant Ovarian Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-03-02"
protocolSection.identificationModule.nctId: "NCT03542669"
protocolSection.identificationModule.officialTitle: "A Phase I Study of Autologous Killer Cell Injection Induced by Dendritic Dells Loaded With 6B11 Anti-idiotype Minibody (6b11 - OCIK Injection) Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.